MCID: HYP069
MIFTS: 58

Hyperparathyroidism

Categories: Genetic diseases, Rare diseases, Endocrine diseases

Aliases & Classifications for Hyperparathyroidism

MalaCards integrated aliases for Hyperparathyroidism:

Name: Hyperparathyroidism 12 72 28 51 41 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:13543
ICD10 32 E21.3
ICD9CM 34 252.0 252.00
MeSH 41 D006961
NCIt 46 C48259
UMLS 69 C0020502

Summaries for Hyperparathyroidism

Disease Ontology : 12 A parathyroid gland disease characterized by an overactivity of the parathyroid glands, leading to an excess of parathyroid hormone in the body.

MalaCards based summary : Hyperparathyroidism is related to hyperparathyroidism 1 and hyperparathyroidism 2 with jaw tumors. An important gene associated with Hyperparathyroidism is CASR (Calcium Sensing Receptor), and among its related pathways/superpathways are Development_Hedgehog and PTH signaling pathways in bone and cartilage development and Transcription_Role of VDR in regulation of genes involved in osteoporosis. The drugs Benzocaine and Sevelamer have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and thyroid, and related phenotypes are cellular and cardiovascular system

Wikipedia : 72 Hyperparathyroidism is an increased parathyroid hormone (PTH) levels in the blood. This occurs either... more...

Related Diseases for Hyperparathyroidism

Diseases in the Hyperparathyroidism family:

Hyperparathyroidism 1 Hyperparathyroidism 3
Hyperparathyroidism 4 Primary Hyperparathyroidism

Diseases related to Hyperparathyroidism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 350)
# Related Disease Score Top Affiliating Genes
1 hyperparathyroidism 1 34.6 CDC73 MEN1
2 hyperparathyroidism 2 with jaw tumors 34.5 CASR CDC73 MEN1 RET
3 hyperparathyroidism 3 34.3 CDC73 GCM2 HRPT3 MEN1
4 hyperparathyroidism, neonatal severe 34.2 CASR PRKAR1A
5 osteitis fibrosa 33.1 BGLAP CALCA CASR PTH
6 familial hypocalciuric hypercalcemia 32.6 CASR CDC73 PTH
7 parathyroid carcinoma 32.4 CALCA CASR CDC73 MEN1 PTH
8 multiple endocrine neoplasia, type iia 32.3 CALCA CDC73 MEN1 PTH RET
9 multiple endocrine neoplasia, type iib 31.8 CALCA MEN1 RET
10 vitamin d-dependent rickets, type 2a 31.6 CYP27B1 VDR
11 multiple endocrine neoplasia, type i 31.2 CASR CDC73 CDKN1B CHGA MEN1 PRKAR1A
12 primary hyperparathyroidism 31.2 BGLAP CALCA CASR CDC73 CDKN1B CHGA
13 secondary hyperparathyroidism of renal origin 31.1 ACP5 BGLAP CALCA CASR CYP27B1 EPO
14 rickets 31.0 BGLAP CYP27B1 FGF23 PHEX PTH VDR
15 parathyroid adenoma 30.8 BGLAP CALCA CASR CDC73 CHGA GCM2
16 calciphylaxis 30.7 CASR FGF23 PTH VDR
17 kidney disease 30.5 CASR EPO FGF23 PTH
18 cohen-gibson syndrome 30.5 BGLAP FGF23 TNFRSF11B
19 pseudohypoparathyroidism 30.3 BGLAP PTH PTHLH
20 hypercalcemia, infantile, 1 30.2 CALCA CASR PRKAR1A PTH PTHLH VDR
21 hyperphosphatemia 30.2 CASR FGF23 GCM2 PTH VDR
22 clear cell adenoma 30.2 MEN1 PTH PTHLH
23 pheochromocytoma 30.2 CALCA CHGA MEN1 RET
24 uremia 30.1 CASR EPO PTH TNFRSF11B VDR
25 parathyroid transitional clear cell adenoma 30.1 MEN1 PTH
26 giant cell tumor 30.0 BGLAP CALCA TNFRSF11B
27 chief cell adenoma 30.0 GCM2 PTH
28 multiple endocrine neoplasia 30.0 CALCA CDKN1B CHGA MEN1 PRKAR1A RET
29 fibrous dysplasia 30.0 BGLAP CALCA CDC73 FGF23
30 calcinosis 29.9 CALCA FGF23 PHEX
31 pseudohypoparathyroidism, type ib 29.9 BGLAP PTH PTHLH
32 thyroid cancer, nonmedullary, 1 29.9 CALCA MEN1 PRKAR1A RET
33 pancreatic islet cell tumors 29.8 CALCA MEN1
34 follicular adenoma 29.8 CALCA CDKN1B RET
35 renal osteodystrophy 29.8 BGLAP CALCA CASR FGF23 PTH TNFRSF11B
36 hypoparathyroidism 29.8 BGLAP CASR FGF23 GCM2 PTH PTHLH
37 hypophosphatemia 29.7 BGLAP FGF23 PHEX PTH
38 invasive malignant thymoma 29.7 PTH PTHLH
39 von hippel-lindau syndrome 29.6 CHGA MEN1 RET
40 oncogenic osteomalacia 29.5 FGF23 PHEX PTH PTHLH
41 hypophosphatemic rickets, x-linked recessive 29.5 CYP27B1 FGF23 PHEX VDR
42 hypervitaminosis d 29.5 CYP27B1 FGF23 PTH
43 osteomalacia 29.4 BGLAP CALCA CASR FGF23 PHEX PTHLH
44 thyroid carcinoma, familial medullary 29.4 CALCA CHGA MEN1 RET
45 hypocalcemia, autosomal dominant 1 29.3 CALCA CASR GCM2 PRKAR1A VDR
46 chronic kidney failure 29.3 BGLAP CALCA CASR CYP27B1 EPO FGF23
47 islet cell tumor 29.3 CALCA CHGA MEN1 PTHLH
48 acute thyroiditis 29.3 CALCA CHGA
49 parathyroid gland disease 29.2 BGLAP CALCA CASR CDC73 FGF23 GCM2
50 hypophosphatemic rickets, x-linked dominant 29.1 CYP27B1 FGF23 PHEX PTH VDR

Comorbidity relations with Hyperparathyroidism via Phenotypic Disease Network (PDN):


Acute Cystitis Chronic Kidney Failure
Deficiency Anemia Hypertension, Essential
Hypoparathyroidism Hypothyroidism
Nephrolithiasis, X-Linked Recessive, with Renal Failure Osteoporosis
Parathyroid Carcinoma

Graphical network of the top 20 diseases related to Hyperparathyroidism:



Diseases related to Hyperparathyroidism

Symptoms & Phenotypes for Hyperparathyroidism

MGI Mouse Phenotypes related to Hyperparathyroidism:

43 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.4 RET TNFRSF11B VDR CASR CDC73 CDKN1B
2 cardiovascular system MP:0005385 10.38 RET TNFRSF11B VDR PTH PTHLH FGF23
3 growth/size/body region MP:0005378 10.36 FGF23 MEN1 PHEX PRKAR1A PTH PTHLH
4 homeostasis/metabolism MP:0005376 10.35 CASR CDC73 CDKN1B CHGA CYP27B1 EPO
5 endocrine/exocrine gland MP:0005379 10.34 CASR CDC73 CDKN1B CHGA CYP27B1 FGF23
6 hematopoietic system MP:0005397 10.31 CASR CDC73 CDKN1B CYP27B1 EPO FGF23
7 immune system MP:0005387 10.3 CASR CDC73 CDKN1B CYP27B1 EPO FGF23
8 craniofacial MP:0005382 10.29 CDC73 CDKN1B CYP27B1 GCM2 MEN1 PHEX
9 digestive/alimentary MP:0005381 10.24 CASR CDC73 CDKN1B FGF23 MEN1 PHEX
10 mortality/aging MP:0010768 10.24 CASR CDC73 CDKN1B CHGA EPO FGF23
11 integument MP:0010771 10.09 CASR CDC73 CDKN1B CYP27B1 EPO FGF23
12 limbs/digits/tail MP:0005371 10.06 CYP27B1 EPO FGF23 PHEX PTH PTHLH
13 adipose tissue MP:0005375 10.05 CDC73 CDKN1B CYP27B1 PHEX PRKAR1A PTHLH
14 renal/urinary system MP:0005367 10 CASR CDC73 CDKN1B CHGA CYP27B1 FGF23
15 muscle MP:0005369 9.97 CASR CDC73 CDKN1B EPO MEN1 PRKAR1A
16 reproductive system MP:0005389 9.85 CDC73 CDKN1B CHGA CYP27B1 FGF23 MEN1
17 respiratory system MP:0005388 9.5 PRKAR1A PTHLH RET CDC73 CDKN1B EPO
18 skeleton MP:0005390 9.44 CYP27B1 EPO FGF23 GCM2 PHEX PRKAR1A

Drugs & Therapeutics for Hyperparathyroidism

Drugs for Hyperparathyroidism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 197)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
2
Sevelamer Approved Phase 4,Phase 3,Phase 2 52757-95-6, 152751-57-0 3085017
3
Calcium acetate Approved, Investigational Phase 4,Phase 3 62-54-4
4
Denosumab Approved Phase 4,Phase 3,Phase 1 615258-40-7
5
Alendronate Approved Phase 4,Phase 2 121268-17-5, 66376-36-1 2088
6
Darbepoetin alfa Approved, Investigational Phase 4 209810-58-2, 11096-26-7
7
Ethanol Approved Phase 4 64-17-5 702
8
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2 471-34-1
9
Zoledronic acid Approved Phase 4,Phase 1 118072-93-8 68740
10
Pamidronate Approved Phase 4 40391-99-9 4674
11
Angiotensin II Approved, Investigational Phase 4,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
12
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
13 Racepinephrine Approved Phase 4 329-65-7
14
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
15
Iron Approved Phase 4 7439-89-6 23925
16
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-14-6 5280793
17 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
18
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1406-16-2
19
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Early Phase 1 67-97-0 10883523 5280795 6221
20
Calcitriol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 32222-06-3 5280453 134070
21
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
22
Alfacalcidol Approved, Nutraceutical Phase 4,Phase 2 41294-56-8 5282181
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 59-30-3 6037
24
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
25
Nicotinamide Approved, Investigational, Nutraceutical Phase 4 98-92-0 936
26 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Calcimimetic Agents Phase 4,Phase 2,Phase 3,Phase 1
28 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Cinacalcet Hydrochloride Phase 4,Phase 2,Phase 3,Phase 1
30 Ergocalciferols Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Vitamins Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
37 1 alpha-hydroxyergocalciferol Phase 4,Phase 3,Phase 2,Phase 1
38 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Retinol palmitate Phase 4
40 Hydroxycholecalciferols Phase 4,Phase 3,Phase 2
41 Calcifediol Phase 4,Phase 3,Phase 1 19356-17-3
42 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1
43 Antimetabolites Phase 4,Phase 2,Phase 1
44 Hypolipidemic Agents Phase 4,Phase 2
45 Lipid Regulating Agents Phase 4,Phase 2
46 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
47 Epoetin alfa Phase 4 113427-24-0
48 Hematinics Phase 4
49 Antioxidants Phase 4
50 Butylated Hydroxytoluene Phase 4

Interventional clinical trials:

(show top 50) (show all 327)

# Name Status NCT ID Phase Drugs
1 Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients Unknown status NCT02338934 Phase 4 Combination Cinacalcet with Vitamin D analogue
2 Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity Unknown status NCT00288873 Phase 4 Ergocalciferol;Cholecalciferol
3 How Bone is Made in Children Receiving Dialysis Unknown status NCT01799317 Phase 4 Vitamin D2
4 Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
5 Optimizing Treatment Programs for Chronic Kidney Disease-mineral and Bone Disorder and Malnutrition Unknown status NCT02005302 Phase 4 1,25(OH)2 Vitamin D3;Vitamin D2
6 Denosumab in Primary Hyperparathyroidism Completed NCT01558115 Phase 4 Denosumab
7 Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism Completed NCT00307840 Phase 4 paricalcitol
8 Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis Completed NCT01181531 Phase 4 Traditional Vitamin D Therapy;Cinacalcet
9 Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism Completed NCT02417389 Phase 4 cinacalcet;Alendronate
10 Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism Completed NCT01143987 Phase 4 Cinacalcet
11 Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation Completed NCT01178450 Phase 4 Cinacalcet
12 Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4 Paricalcitol injection;Paricalcitol capsules
13 A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer Completed NCT00037518 Phase 4 AMG 073
14 Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate Completed NCT01222026 Phase 4 Strontium Ranelate + Ca/Vitamin-D;Placebo
15 Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism Completed NCT01115543 Phase 4 alfacalcidol and calcitriol
16 ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism Completed NCT00135304 Phase 4 Sensipar®;Vitamin D
17 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. Completed NCT01939977 Phase 4 Paricalcitol;Calcifediol
18 Evaluation of a Cincalcet Suppression Test Completed NCT01103206 Phase 4 cinacalcet;cinacalcet dose 1;cinacalcet dose 2
19 Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) Completed NCT00823303 Phase 4 Paricalcitol;Calcitriol
20 Vitamin D Repletion in Primary Hyperparathyroidism Completed NCT01306656 Phase 4 10,000 IU Vitamin D3
21 START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Completed NCT00132431 Phase 4 Sensipar
22 Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism Completed NCT00123461 Phase 4 Hectorol (doxercalciferol capsules), 0.5mcg
23 Treatment Adhesion in Dialysis Patients Treated With Cinacalcet Completed NCT01573520 Phase 4
24 Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed NCT00891813 Phase 4 Zemplar (paricalcitol)
25 Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level Completed NCT01101113 Phase 4 cinacalcet;control
26 20070360 Incident Dialysis Completed NCT00803712 Phase 4 Cinacalcet;Vitamin D
27 A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection Completed NCT00463021 Phase 4 Hectorol (doxercalciferol capsules);Zemplar (paricalcitol injection)
28 A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis Completed NCT00418600 Phase 4 Hectorol® (doxercalciferol capsules);doxercalciferol capsules, Hectorol®;doxercalciferol capsules, Hectorol® capsules
29 Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients Completed NCT00958451 Phase 4 Paricalcitol;Ergocalciferol
30 The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid Completed NCT02056730 Phase 4 calcium sensing receptor agonist
31 Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium Completed NCT00073710 Phase 4 Zemplar;Calcijex
32 Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D Completed NCT00977080 Phase 4 Paricalcitol;Cinacalcet
33 A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis Completed NCT00454350 Phase 4 Hectorol (doxercalciferol injection);Zemplar (Paricalcitol injection)
34 How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis Completed NCT00528788 Phase 4 doxercalciferol
35 A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) Completed NCT00431496 Phase 4 Cinacalcet
36 A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients Completed NCT01506947 Phase 4 Paricalcitol;Darbepoetin alfa
37 Paricalcitol Effect on Anemia in CKD Completed NCT01768351 Phase 4 Paricalcitol;Calcitriol
38 Trial to Optimize Mineral Outcomes in Dialysis Patients Completed NCT01100723 Phase 4
39 Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis Completed NCT00053547 Phase 4 paricalcitol injection
40 A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease Completed NCT00257920 Phase 4 Zemplar® injection;Hectorol® injection
41 Vitamin D and Coronary Calcification Study Completed NCT00752102 Phase 4 Calcitriol (Rocaltrol®);Paricalcitol
42 A Research Study for Patients With End-Stage Renal Disease (ESRD) Completed NCT00110890 Phase 4 cinacalcet
43 Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density Completed NCT01025128 Phase 4 25 OH vitamin D
44 CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
45 Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease Completed NCT00395382 Phase 4 Alendronate;Placebo
46 Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder Completed NCT01633853 Phase 4 Vitamin D2;1,25(OH)2 Vit D3
47 Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol Completed NCT01748396 Phase 4 Calcitriol;Calcium Carbonate
48 Prospective Study of Profile of Hepatic Osteodystrophy in Patients With Non-Choleastatic Liver Cirrhosis and Impact of Bisphosphonate Supplementation Completed NCT02249741 Phase 4 Treated with Ibandronic acid as per protocol
49 Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney Completed NCT00442819 Phase 4
50 Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy Completed NCT00319761 Phase 4 Calcitriol

Search NIH Clinical Center for Hyperparathyroidism

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: hyperparathyroidism

Genetic Tests for Hyperparathyroidism

Genetic tests related to Hyperparathyroidism:

# Genetic test Affiliating Genes
1 Hyperparathyroidism 28

Anatomical Context for Hyperparathyroidism

MalaCards organs/tissues related to Hyperparathyroidism:

38
Kidney, Bone, Thyroid, Testes, Endothelial, Liver, Heart

Publications for Hyperparathyroidism

Articles related to Hyperparathyroidism:

(show top 50) (show all 2047)
# Title Authors Year
1
Long-Term Skeletal Outcomes of Primary Hyperparathyroidism Patients After Treatment with Parathyroidectomy: A Systematic Review and Meta-Analysis. ( 29381879 )
2018
2
Protective Effect of Denosumab on Bone in Older Women with Primary Hyperparathyroidism. ( 29364518 )
2018
3
Biochemical and pathologic factors affecting technetium-99m-methoxyisobutylisonitrile imaging results in patients with primary hyperparathyroidism. ( 29404934 )
2018
4
Probability of Positive Genetic Testing Results in Patients with Family History of Primary Hyperparathyroidism. ( 29408534 )
2018
5
Calciphylaxis as cutaneous marker of hyperparathyroidism and successful outcome with parathyroidectomy followed by hyperbaric oxygen therapy. ( 29451194 )
2018
6
Uremic leontiasis ossea, a rare presentation of severe renal osteodystrophy secondary to hyperparathyroidism. ( 29037869 )
2018
7
Current opinions on nephrolithiasis associated with primary hyperparathyroidism. ( 29350243 )
2018
8
Primary hyperparathyroidism diagnosed and treated surgically during pregnancy. ( 29429952 )
2018
9
Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients. ( 29439405 )
2018
10
Hyperparathyroidism Mimicking Metastatic Bone Disease: A Case Report and Review of Literature. ( 29446693 )
2018
11
Managing hyperparathyroidism in hemodialysis: role of etelcalcetide. ( 29440923 )
2018
12
Pre-operative localization of abnormal parathyroid tissue by<sup>99m</sup>Tc-sestamibi in primary hyperparathyroidism using four-quadrant site analysis: an evaluation of the predictive value of vitamin D deficiency. ( 29404903 )
2018
13
Clinical usefulness of intraoperative parathyroid hormone monitoring for primary hyperparathyroidism. ( 29441335 )
2018
14
Periosteal chondroma of the cuboid with secondary aneurysmal bone cyst in a setting of secondary hyperparathyroidism. ( 29413778 )
2018
15
Dual energy computed tomography should be the first line preoperative localization imaging test for primary hyperparathyroidism patients. ( 29370881 )
2018
16
Effect of parathyroidectomy on quality of life and non-specific symptoms in normocalcaemic primary hyperparathyroidism. ( 29405278 )
2018
17
Cortical and trabecular bone are equally affected in rats with renal failure and secondary hyperparathyroidism. ( 29394885 )
2018
18
Rare Undiagnosed Primary Amyloidosis Unmasked During Surgical Treatment of Primary Hyperparathyroidism: A Case Report. ( 29359203 )
2018
19
Classic Primary Hyperparathyroidism Versus Normocalcemic and Normohormonal Variants: Do They Really Differ? ( 29392434 )
2018
20
Predictors of Readmission and Reoperation in Patients Undergoing Parathyroidectomy for Primary Hyperparathyroidism. ( 29436275 )
2018
21
The relationship between semiquantitative parameters derived from technetium-99m metoxyisobutylisonitrile dual-phase parathyroid single-photon emission computed tomography images and disease severity in primary hyperparathyroidism. ( 29360693 )
2018
22
Occult urolithiasis in asymptomatic primary hyperparathyroidism. ( 29400579 )
2018
23
Familial isolated primary hyperparathyroidism associated with germline GCM2 mutations is more aggressive and has a lesser rate of biochemical cure. ( 29108698 )
2018
24
Familial Hypocalciuric Hypercalcemia as an Atypical Form of Primary Hyperparathyroidism. ( 29115694 )
2018
25
Influence of Parathyroidectomy on Bone Metabolism and Bone Pain in Patients with Secondary Hyperparathyroidism. ( 29393259 )
2018
26
Normocalcaemic primary hyperparathyroidism: a pragmatic approach. ( 29437827 )
2018
27
Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes. ( 29423207 )
2018
28
Re: Surgery for Primary Hyperparathyroidism: Adherence to Consensus Guidelines in an Academic Health System. ( 29357552 )
2018
29
Cinacalcet versus Placebo for secondary hyperparathyroidism in chronic kidney disease patients: a meta-analysis of randomized controlled trials and trial sequential analysis. ( 29449603 )
2018
30
Influence of concurrent chronic kidney disease on intraoperative parathyroid hormone monitoring during parathyroidectomy for primary hyperparathyroidism. ( 29128188 )
2018
31
Trabecular Bone Score in Obese and Non-obese Subjects with Primary Hyperparathyroidism Before and After Parathyroidectomy. ( 29373705 )
2018
32
Bipolar Disorder With Mixed Features Associated With Primary Hyperparathyroidism. ( 28010754 )
2017
33
FREE AND BIOAVAILABLE 25-HYDROXYVITAMIN D LEVELS IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM. ( 27682354 )
2017
34
Primary hyperparathyroidism: Dynamic postoperative metabolic changes. ( 28906021 )
2017
35
Osteitis fibrosa cystica-a forgotten radiological feature of primary hyperparathyroidism. ( 28900835 )
2017
36
Unilateral Clearance for Primary Hyperparathyroidism in Selected Patients with Multiple Endocrine Neoplasia Type 1: Reply. ( 27847968 )
2017
37
Parathyroidectomy in Hyperparathyroidism-Associated Calciphylaxis in End-Stage Renal Disease Should be Prompt and Radical - a Case Report with Two Original Therapeutic Modifications and Successful Outcome. ( 28976876 )
2017
38
Percentage arterial enhancement: An objective index for accurate identification of parathyroid adenoma/hyperplasia inA primary hyperparathyroidism. ( 28656592 )
2017
39
Management of secondary hyperparathyroidism: how and why? ( 28044233 )
2017
40
Effect of parathyroidectomy on osteopontin and undercarboxylated osteocalcin in patients with primary hyperparathyroidism. ( 28937873 )
2017
41
Comparative Diagnostic Performance of Ultrasonography and 99mTc-Sestamibi Scintigraphy for Parathyroid Adenoma in Primary Hyperparathyroidism; Systematic Review and Meta- Analysis ( 29281866 )
2017
42
Osteolytic lesions: osteitis fibrosa cystica in the setting of severe primary hyperparathyroidism. ( 28554885 )
2017
43
CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism. ( 29040582 )
2017
44
Concomitant occurrence of primary hyperparathyroidism (PHPT) due to mediastinal parathyroid adenoma and sublingual thyroid gland: the role of parathyroid technetium-99m-MIBI scintigraphy. ( 29152292 )
2017
45
Association of ADAMTS4 and ADAMTS9 levels with cardiovascular risk in patients with primary hyperparathyroidism. ( 28937860 )
2017
46
Primary hyperparathyroidism caused by enormous unilateral water-clear cell parathyroid hyperplasia. ( 28888222 )
2017
47
A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. ( 28057872 )
2017
48
Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis. ( 28063122 )
2017
49
Atypical intraosseous meningioma with growth hormone deficiency and hyperparathyroidism after craniospinal irradiation. ( 28948343 )
2017
50
Anesthetic management of primary hyperparathyroidism during pregnancy: A case report. ( 29390544 )
2017

Variations for Hyperparathyroidism

Expression for Hyperparathyroidism

Search GEO for disease gene expression data for Hyperparathyroidism.

Pathways for Hyperparathyroidism

GO Terms for Hyperparathyroidism

Cellular components related to Hyperparathyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 BGLAP CALCA CHGA EPO FGF23 PTH

Biological processes related to Hyperparathyroidism according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.97 CALCA EPO FGF23 PTH PTHLH TNFRSF11B
2 response to drug GO:0042493 9.96 BGLAP CDKN1B PTH RET TNFRSF11B
3 negative regulation of cell proliferation GO:0008285 9.95 CDC73 CDKN1B CYP27B1 MEN1 PTHLH VDR
4 response to lipopolysaccharide GO:0032496 9.89 ACP5 CYP27B1 EPO TNFRSF11B
5 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.79 CALCA PTH PTHLH
6 negative regulation of epithelial cell proliferation GO:0050680 9.77 CDC73 CDKN1B MEN1
7 positive regulation of cAMP biosynthetic process GO:0030819 9.75 CALCA PTH PTHLH
8 bone mineralization GO:0030282 9.72 BGLAP CYP27B1 PHEX
9 cellular calcium ion homeostasis GO:0006874 9.72 CALCA CASR GCM2 PTH VDR
10 response to estrogen GO:0043627 9.67 BGLAP CYP27B1 EPO TNFRSF11B
11 negative regulation of chondrocyte differentiation GO:0032331 9.65 PTH PTHLH
12 positive regulation of ossification GO:0045778 9.65 CALCA PTH
13 response to inorganic substance GO:0010035 9.65 BGLAP TNFRSF11B
14 positive regulation of keratinocyte differentiation GO:0045618 9.64 CYP27B1 VDR
15 response to magnesium ion GO:0032026 9.64 FGF23 TNFRSF11B
16 positive regulation of cAMP metabolic process GO:0030816 9.63 CALCA CHGA
17 negative regulation of bone resorption GO:0045779 9.63 CALCA TNFRSF11B
18 decidualization GO:0046697 9.63 CYP27B1 MEN1 VDR
19 vitamin D metabolic process GO:0042359 9.62 CYP27B1 FGF23
20 cellular phosphate ion homeostasis GO:0030643 9.62 FGF23 GCM2
21 cellular response to parathyroid hormone stimulus GO:0071374 9.61 FGF23 PHEX
22 regulation of bone mineralization GO:0030500 9.61 BGLAP CYP27B1 FGF23
23 response to fibroblast growth factor GO:0071774 9.58 CASR PTH
24 osteoblast development GO:0002076 9.58 BGLAP MEN1 PTHLH
25 negative regulation of calcium ion transport into cytosol GO:0010523 9.57 CALCA EPO
26 response to vitamin D GO:0033280 9.56 BGLAP CYP27B1 PHEX PTH
27 cAMP metabolic process GO:0046058 9.54 PTH PTHLH
28 vitamin D catabolic process GO:0042369 9.52 CYP27B1 FGF23
29 response to sodium phosphate GO:1904383 9.51 FGF23 PHEX
30 skeletal system development GO:0001501 9.43 BGLAP PHEX PTH PTHLH TNFRSF11B VDR
31 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.33 CYP27B1 FGF23 VDR
32 cellular response to vitamin D GO:0071305 8.92 BGLAP CASR FGF23 PHEX

Molecular functions related to Hyperparathyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide hormone receptor binding GO:0051428 8.96 PTH PTHLH
2 hormone activity GO:0005179 8.92 CALCA EPO PTH PTHLH

Sources for Hyperparathyroidism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....